Severe obstructive sleep apnoea (OSA) is an important risk factor for developing glaucoma and must be treated in those who have it to improve control of the eye disease, according to new research.
Severe obstructive sleep apnoea (OSA) is an important risk factor for developing glaucoma and must be treated in those who have it to improve control of the eye disease, according to new research published in Eye.
Researchers in Qatar assessed for glaucoma in 39 adults who had been diagnosed with moderate or severe OSA. They classified the severity of OSA as mild, moderate, or severe using American Association of Sleep Medicine (AASM) criteria and the apnoea hypopnoea index. All study participants underwent serial visual field tests, optical coherence tomography with fundus photography, and pachymetry before the study began, and they were followed in an ophthalmology outpatient clinic and a sleep clinic for 3 years.
The investigators discovered that 8 (20.5%) of the study participants who had OSA also had glaucoma; 6 (75%) of them had normal-tension glaucoma (NTG), and 2 (25%) had the high-tension version. Among the 27 participants in whom OSA was classified as severe, the eye disease was present in 7 (25.9%), and among 12 patients with moderate OSA, the eye disease was present in 1 (8.3%).
During follow-up, two participants in whom glaucoma originally had not been diagnosed were reclassified as having NTG. Also, the condition of two participants who had glaucoma deteriorated. A higher prevalence of glaucoma existed in those with severe OSA than in those with moderate OSA, although the difference was not statistically significant.
For more detailed information visit the journal's website.
AAO 2024: Transient vision loss with Alexander Fein, MD
October 21st 2024Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might be needed to determine the best plan for care.
AAO 2024: Optimal pupil size reduction percentage for near vision improvement in presbyopia
October 21st 2024Jennifer Loh, MD, shared insights from on her presentation at the American Academy of Ophthalmology meeting in Chicago on the effects of CSF-1, which is the lowest effective concentration of pilocarpine approved in the United States.